EXPERIENCE OF USE OF HEPABENE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS


Cite item

Full Text

Abstract

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease developing in patients who do not consume alcohol in hepatotoxic doses, and is characterized by the development macrovesicular steatosis and lobular inflammation of the liver. NASH is considered as a disease of the liver in the metabolic syndrome, the pathogenetic basis of which is the development of insulin resistance. The results of open clinical study of efficacy and safety of herbal medicine Hepabene (milk thistle and fumitory extracts) in the treatment of 43 patients with NASH are presented. It was shown that treatment of NASH with the drug Hepabene due to restoration of hepatocyte function and normalization of bile outflow leads to rapid improvement of general state of patients, reduction of severity of clinical symptoms, laboratory and instrumental parameters. The drug effectively restores motor-evacuatory function of the biliary tract; Hepabene is well tolerated by patients and can be recommended for use in the treatment of patients with NASH, especially with concomitant biliary tract disease.

References

  1. Буеверов А.О. Неалкогольная жировая болезнь печени и неалкогольный стеатогепатит // Врач. 2006. № 7. С. 33-37.
  2. Болезни печени и желчевыводящих путей: Руководство для врачей / Под редакцией В.Т. Ивашкина М., 2002.
  3. Винницкая E.В. Применение гепабене в лечении хронических гепатитов // Фарматека. 2004. № 19-20 (96). С. 91-96.
  4. Вовк А.Н., Зайцева О.В., Федотов Н.Г., Бушуев С.Л. Эффективность применения препарата гепабене у детей с дисфункциональными расстройствами билиарного тракта // Педиатрия. 2003. № 5. С. 72-75.
  5. Дягтерева И.И., Оседло Г.В., Скрыпник И.Н., и др. Обоснование применения Гепабене для лечения больных с хроническими гепатитами токсической этиологии и жировой дистрофией печени в сочетании с хроническими заболеваниями желчного пузыря // Сачасна гастроэнтерологiя. 2003. № 3. С. 51-54.
  6. Ильченко Л.Ю. Гепабене в лечении гепатобилиарной системы у пожилых // Русский медицинский журнал. 2003. № 1. С. 24-27.
  7. Ильченко А.А., Орлова Ю.Н. Применение гепабене у больных хроническим холециститом. Материалы 3-го Росс. науч. Форума "Санкт-Петербург - Гастро-2001" // Гастробюллетень. 2001. № 2-3. С. 39.
  8. Ильченко Л.Ю., Егорова Е.Г. Неалкогольный стеатогепатит // Качество жизни. Медицина. 2007. № 4. С. 37-41.
  9. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population - based cohot study. Gastroenteroligy. 2005;129(1):113-21.
  10. Buglianesi E, McCullough AJ, Marchesini G. Insulin resistance: Ametabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000.
  11. Feher J, Nemeth E, Lengyel G. Nonalcoholic stetohepatitis - is it a part of the metabolic syndrome? Arch Мed Sci 2005;1(1):37-47.
  12. Gupte P, Amarapurkar D, Agal S, et al. Nonalcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-58.
  13. Kojima H, Sakurai S, Matsumura M, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. J Gastroenterol 2006;7:2080-85.
  14. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
  15. Neuschwander-Tetri BA, Сaldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Singl Topic Conference. Hepatology 2003;37:1202-19.
  16. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary model of nonalcoholic steatohepatitis Gastroenterology 2007;132:282-93.
  17. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35(2):367-72.
  18. Scheen AJ, Luycks FH. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Acta Clin Belg 2003;58:81-91.
  19. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-23.
  20. Rotter V, Nagaev I, Smith U. Interleukin - 6 Induces Insulin Resistance in 3T3 - L1 Adipocytes and Is, Like interleukin - 8 and Tumor Necrosis Factor - a, Overexpressed in Human Fat Сells from Insulin - resistant Subjects. Biol Chem 2003;278(46):45777-84.
  21. Valenti L. Tumor necrosis factor - alfa promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-80.
  22. Tang DC, et al. FA oxidation and signaling in apoptosis. Biol Chem 2002;383:425-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies